© 1999 by European Society of Cardiology
Assessment of accessory pathway and atrial refractoriness by transoesophageal and intracardiac atrial stimulation
An analysis of methodological agreement
Department of Cardiology, Karolinska Hospital Stockholm, Sweden
Aims
Measurement of the refractory properties of asymptomatic overt accessory pathways is performed to assess the risk for significant arrhythmias. We hypothesized that a transoesophageal atrial stimulation (TAS) protocol would accurately predict simultaneously measured invasive intra cardiac stimulation (ICS) of the anterograde effective refractory period of the accessory pathway (AP-ERP)
Methods and Results
Fourteen single pathway Wolff-Parkinson-White (WPW) syndrome patients underwent TAS during ICS and 24 h prior to it. The AP-ERP was measured using incremental atrial extra stimuli from TAS, the right atrium (RA) and the coronary sinus (CS) using drive trains of 500 and 600 ms. Stimulus latency was measured from intracardiac electrocardiograms. For methodological comparison, Altman–Bland analysis was used to create the limits of agreement (within-patient mean of differences±two standard deviations). There were no or small differences in the AP-ERP, as assessed by TAS, compared to RA and CS. Methodological disagreement between the three sites were common, however, and the limits of agreement ranged from ±30 to±76 ms. The concordance between TAS and RA, with regards to the AP-ERP value of 270 ms, was 63% when measured as S1S2 and was 67% when measured as A1A2. The stimulation site delay was significantly shorter for TAS compared to RA and CS sites. The two TAS procedures performed a day apart, revealed a coefficient of variation of 9% and a coefficient of reproducibility of 63 ms.
Conclusions
Despite adequate reproducibility, TAS fails to predict the AP-ERP by ICS. Differences in stimulus latency is responsible, in part, for the disagreement. In-vasive ICS cannot be replaced by TAS for risk stratifying WPW patients.
Key Words: Transoesophageal atrial stimulation, accessory, pathway refractory period, WolV-Parkinson-White syndrome, electrophysiological study, methodological agreement
Correspondence: Börje Darpö MD, PhD, Department of Cardiology, Karolinska Hospital, Box 110, S-104 01 Stockholm, Sweden.
[1] B-Lundqvist C and Edvardsson N. Transesophageal versus intracardiac atrial stimulation in assessing electrophysiological parameters of the sinus and AV nodes and of the atrial myocardium. PACE 1987; 10: 1081–1095.
[2] Alboni P, Paparella N, Cappato R, Pedroni P, Candini GC, Antonioli GE. Reliability of transesophageal pacing in the assessment of sinus node function in patients with sick sinus syndrome. PACE 1989; 12: 294–299.
[3] Guarneiro M, Furlanello F, Vergaro G, et al. Electropharmacological testing by transoesophageal atrial pacing in inducible supraventricular tachyarrhythmias. Eur Heart J 1992; 13: 763–769.
[4] Kerr CR, Gallagher JJ, Smith WM, Sterba R, German LD, Kasell JH. The induction of atrial flutter and fibrillation and the termination of atrial flutter by esophageal pacing. PACE 1983; 6: 60–72.
[5] Drago F, Turchetta A, Calzolari A, et al. Detection of atrial tachyarrhythmias by transesophageal pacing and recording at rest and during exercise in children with ventricular preexcitation. Am J Cardiol 1992; 69: 1098–1199.[CrossRef][Web of Science][Medline]
[6] Volkmann H, Kuhnert H, Dannberg G. Electrophysiological evaluation of tachycardias using transesophageal pacing and recording. PACE 1990; 13: 2044–2047.
[7] Critelli G, Grassi G, Perticone F, Coltori F, Monda V, Condorelli M. Transesophageal pacing for prognostic evaluation of preexcitation syndrome and assessment of protective therapy. Am J Cardiol 1983; 51: 513–518.[CrossRef][Web of Science][Medline]
[8] Kulakowski P, Dluzniewski M, O'Nunain S, Camm J, Wardzynska M, Ceremuzynski L. The value of transesophageal atrial pacing in predicting the efficacy of antiarrhythmic drugs in patients with paroxysmal narrow QRS complex tachycardia. PACE 1992; 15: 895–904.
[9] Darpö B, Almgren O, Bergstrand R, et al. Tolerance and effects of almokalant, a new selective Ik blocking agent, on ventricular repolarization and on sino-atrial and AV nodal function in the heart. A study in healthy, male volunteers utilizing transesophageal atrial stimulation. J Cardiovasc Pharmacol 1995; 25: 681–690.[Web of Science][Medline]
[10] Darpö B and Edvardsson N. The eYcacy of almokalant, a selective Ik blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias. A study in patients with Wolff-Parkinson-White syndrome and AV nodal reentrant tachycardia using transesophageal atrial electrodes. J Cardiovasc Pharmacol 1995; 26: 198–206.[Web of Science][Medline]
[11] Darpö B and Edvardsson N. The effects of almokalant, a class III antiarrhythmic agent, on supraventricular, reentrant tachycardias. Cardiovasc Drugs Ther 1997; 11: 499–508.[CrossRef][Web of Science][Medline]
[12] Kennebäck G, Bergfeldt L, Tomson T. Electrophysiological evaluation of the sodium-channel blocker carbamazepine in healthy human subjects. Cardiovasc Drugs Ther 1995; 9: 709–714.[CrossRef][Web of Science][Medline]
[13] Leitch JW, Klein GJ, Yee R, Murdock C. Prognostic value of electrophysiology testing in asymptomatic patients with Wolff-Parkinson-White pattern. Circulation 1990; 82: 1718–1723.
[14] Milstein S, Sharma AD, Klein GJ. Electrophysiologic profile of asymptomatic Wolff-Parkinson-White pattern. Am J Cardiol 1986; 57: 1097–1100.[CrossRef][Web of Science][Medline]
[15] Wellens HJ and Durrer D. Wolf-Parkinson-White syndrome and atrial fibrillation. Am J Cardiol 1974; 34: 777–782.[CrossRef][Medline]
[16] Castellanos A, Myeburg RJ, Craparo K, Befeler B, Agha AS. Factors regulating ventricular rates during atrial flutter and fibrillation in pre-excitation syndrome. Br Heart J 1973; 35: 811–816.
[17] Fujimura O, Klein GJ, Yee R, Sharma A. Mode of onset of atrial fibrillation in the Wolff-Parkinson-White syndrome: How important is the accessory pathway? J Am Coll Cardiol 1990; 15: 1082–1086.[Abstract]
[18] Della Bella P, Brugada P, Talajic M, et al. Atrial fibrillation in patients with accessory pathway: Importance of the conduction properties of the accessory pathway. J Am Coll Cardiol 1991; 17: 1352–1356.[Abstract]
[19] Beckman KJ, Gallastegui JL, Bauman JL, Hariman RJ. The predictive value of electrophysiologic studies in untreated patients with Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1990; 15: 640–647.[Abstract]
[20] Auricchio A, Klein H, Trappe H-J, Wenzlaff P. Lack of prognostic value of syncope in patients with Wolff-Parkinson-White syndrome. Am Coll Cardiol 1991; 17: 152–158.[Abstract]
[21] Sharma A D, Yee R, Guiraudon G, Klein G. Sensitivity and specificity of invasive and noninvasive testing for risk of sudden death in Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1987; 10: 373–381.[Abstract]
[22] Waldo AL, Akhtar M, Benditt DG, et al. Appropriate electrophysiological study and treatment of patients with Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1988; 11: 1124–1129.[Web of Science][Medline]
[23] Packer DL, Pressley JC, German LD, Prystowsky EN. Accuracy of invasive testing for direct identification of sudden cardiac death risk in the Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1988; 11: 78A.
[24] Klein GJ, Yee R, Sharma AD. Longitudinal electrophysiologic assessment of asymptomatic patients with Wolff-Parkinson-White electrocardiographic pattern. N Engl J Med 1989; 320: 1229–1233.[Abstract]
[25] Munger TM, Packer DL, Hammill SC, et al. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmstead county, Minnesota, 1953–1989. Circulation 1993; 87: 866–873.
[26] Gallagher JJ, Smith WM, Kerr CR, et al. Esophageal pacing: A diagnostic and therapeutic tool. Circulation 1982; 65: 336–341.
[27] Santini M, Ansalone G, Cacciatore G, Turitto G. Transesophageal pacing. PACE 1990; 13: 1298–1325.
[28] Bland JM and Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307–310.[CrossRef][Web of Science][Medline]
[29] Franz M, Bargheer K, Rafflenbeul W, Haverich A, Lichtlen P. Monophasic action potential mapping in human subjects with normal electrocardiograms: direct evidence for the genesis of the T wave. Circulation 1987; 75: 379–386.
[30] Mitchell B, Wyse G, Duff H. Programmmed electrical stimulation studies for ventricular tachycardia induction in humans. I. Role of ventricular functional refractoriness in tachycardia induction. J Am Coll Cardiol 1986; 8: 567–575.[Abstract]
[31] Kennebäck G and Bergfeldt L. Transesophageal atrial stimulation. A study on reproducibility in normal subjects. Eur J Cardiac Pacing Electrophysiol 1994; 2: 108–115.
[32] Benson DWJ, Jadvar H, Strasburger J. Utility of stimulus artifact suppressor for transesophageal pacing. Am J Cardiol 1990; 65: 393–394.[CrossRef][Web of Science][Medline]
[33] Favale S, Minafra F, Massari V, Tritto M, Rizzon P. Transesophageal versus intracardiac atrial stimulation in assessing anterograde conduction properties of the accessory pathway in Wolff-Parkinson White syndrome. Int J Cardiol 1991; 30: 209–214.[CrossRef][Web of Science][Medline]
[34] Samson R, Deal B, Strasburger J, Benson W. Comparison of transesophageal and intracardiac electrophysiological studies in characterization of supraventricular tachycardia in pediatric patients. J Am Coll Cardiol 1995; 26: 159–163.[Abstract]
[35] Klein GJ, Basore TM, Sellers TD, Pritchett ELC, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979; 301: 1080–1085.[Abstract]
[36] Bergfeldt L, Melander H, Schenk-Gustavsson K. Timedependent variation in the cardiac conduction system assessed in young healthy individuals at week's interval. Implications for clinical trials. J Am Coll Cardiol 1991; 18: 792–800.[Abstract]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Task Force on Syncope, European Society of Cardiol, M Brignole, P Alboni, D Benditt, L Bergfeldt, J.J Blanc, P.E Bloch Thomsen, J.G van Dijk, A Fitzpatrick, S Hohnloser, et al. Guidelines on management (diagnosis and treatment) of syncope Eur. Heart J., August 1, 2001; 22(15): 1256 - 1306. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||